Drugs / Imipenem/Cilastatin/Relebactam
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04983901 | Sep 2021 → Oct 2023 | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imipenem/Cilastatin/Relebactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04983901 ↗ |
| Route | Intravenous | “Given IV” NCT04983901 ↗ |